Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado mayo 2022

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

EudraCT-NumberNCTCÓDIGO-ESTUDIOTÍTULO ESTUDIO FASEINDICACIÓNESTADOMEDICACIÓNCENTROPROMOTOR
N.A4970134
TTCC-2020-02Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY ProjectObservacionalThis project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation.RECLUTANDON.AH.U. Clínic (Barcelona)
H.U. Miguel Servet (Zaragoza)
H.U. La Paz (Madrid)
H.U. La Fe (Valencia)
H.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. Marqués de Valdecilla (Santander)
ICO Hospitalet
H. General de Valencia
Fundación Althaia (Manresa)
H.U. Parc Taulí (Sabadell)
ICO Girona
TTCC
2018-004334-15
4234113SC103A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid TumorsPhase IHNSCC & Thyroid, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selectedadvanced/metastatic solid tumorsRECLUTANDOSO-C101 PembrolizumaH.U. Vall d´Hebron (Barcelona)SOTIO
2017-000800-59
3157128
LOXO-RET-17001A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)Phase I/IIThis is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.RECLUTANDOLOXO-292H.U. Vall d´Hebron (Barcelona)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc
2018-001066-42
3753919GETNE-T1812A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY TrialPhase IIThis is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.RECLUTANDODurvalumab
Tremelimumab
CUN
H.U. Vall d´Hebron (Barcelona)
ICO Hospitalet
H.U. Morales Meseguer (Murcia)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Virgen de la Victoria (Málaga)
H.U. Clínic (Barcelona)
M.D. Anderson (Madrid)
H.U. Sanchinarro (Madrid)
H.U. Clínico San Carlos (Madrid)
C.H. Castellón
IVO Valencia
H.U. Alvaro Cunqueiro (Vigo)
Spanish Group of Neuroendocrine Tumors (GETNE)
2016-003616-133093116TPX-0005-01A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)Phase II (in Spain)A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)RECLUTANDORepotrectinib (TPX-0005)CUN
H.U. Dexeus (Barcelona)
H.U. Vall d´Hebron (Barcelona)
M.D. Anderson (Madrid)
Start_F.J.Díaz (Madrid)
Start_Sanchinarro (Madrid)
H.U. 12 de Octubre (Madrid)
IVO Valencia
Turning Point Therapeutics, Inc.
2019-002279-32
4400474GETNE-T1914Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN StudyPhase IICABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.RECLUTANDO
cabozantinib
atezolizumab 
15 CentrosSpanish Group of Neuroendocrine Tumors (GETNE) & Ipsen/Roche Pharma AG
2015-002067-4126280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECLUTANDOPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
Merck Sharp & Dohme Corp
UK3906331J2G-OX-Y001Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationExpanded AccessMedullary Thyroid Cancer
Papillary Thyroid Cancer
Other Solid Tumors With Evidence of Activating RET Alteration
RECLUTANDOSelpercatinibH.U. Vall d´Hebron (Barcelona)
Start_Sanchinarro (Madrid)
Loxo Oncology, Inc.
2019-001978-284211337J2G-MC-JZJBA Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)Phase IIIThe reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body.RECLUTANDOSelpercatinib
Cabozantinib
Vandetanib
H.U. Virgen de la Victoria (Málaga)
H.U. Clínico San Carlos (Madrid)
H.U. 12 de Octubre (Madrid)
H.U. La Paz (Madrid)
H.U. Ramón y Cajal (Madrid)
H.U. Gregorio Marañón (Madrid)
ICO Girona
ICO Hospitalet
H.U. Vall d´Hebron (Barcelona)
C.U.N.
H.U. Miguel Servet (Zaragoza)
Loxo Oncology, Inc
2020-005269-154760288CO42865A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.Phase IIIA study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy.RECLUTANDOPralsetinib
Cabozantinib
Vandetanib
H.U.Santiago Compostela
CUNavarra
H.Vall d´Hebron
H Clinic (BCN)
MDAnderson(Madrid)
H.Ramon y Cajal
H.Sanchinarro
H.Regional Malaga
H.Virgen del Rocio(Sevilla)
Hoffmann-La Roche
N.A3765333
REGETNE-TiroidesDescriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and AnaplasticDescriptive ObservationalNARECLUTANDONAH.U. Vall d´Hebron (Barcelona)GETNE

Puede seleccionar el número de filas a representar entre: 4, 8 o 10